Blueprint
 
 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported):  June 26, 2018
 
Commission File Number:  001-37761
 
VistaGen Therapeutics, Inc.
(Exact name of registrant as specified in its charter.)
 
Nevada
(State or other jurisdiction of incorporation or organization)
205093315
(IRS Employer Identification No.)
 
343 Allerton Avenue, South San Francisco, California 94080
(Address of principal executive offices)
 
650-577-3600
(Registrant's Telephone number)
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)
Emerging growth company [ ]
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
 
 

 
 
 
 
 
Item 2.02      Results of Operations and Financial Condition.
 
See Item 8.01.
 
Item 8.01      Other Events.
 
On June 26, 2018, VistaGen Therapeutics, Inc. (the “Company”) issued a press release to provide investors with a corporate update and to announce the Company’s financial results for its fiscal year ended March 31, 2018. A copy of the press release is attached hereto as Exhibit 99.1.
 
The information furnished herein and therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
 
Item 9.01      Financial Statements and Exhibits.
 
See Exhibit Index. 
 
Disclaimer.
 
This Current Report on Form 8-K may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements with respect to the Company's plans, objectives, expectations and intentions; and (ii) other statements identified by words such as “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties.
 
 
-2-
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
VistaGen Therapeutics, Inc. 
Date: June 27, 2018
  
 
 
By:
/s/ Shawn K. Singh
 
Name:
Title:
Shawn K. Singh
Chief Executive Officer
 
 
-3-
 
 
EXHIBIT INDEX
 
 
Exhibit Number
 
Description
 
 
 
 
Press release issued by VistaGen Therapeutics, Inc. dated June 26, 2018.
 
 
 
 
 
 
-4-